6505--36C77026Q0061/RFI/Domestic Sources Rx_MedSurge

Description

{"description":"36C77026Q0061\nRequest for Information (RFI): \nDomestic Pharmaceutical Manufacturing 36C77026Q0061\n1. Overview\nThe Department of Veterans Affairs (VA), Consolidated Mail Outpatient Pharmacy (CMOP) operates seven sites across the United States, supporting the daily mailout of approximately 450,000 prescriptions to Veterans. While the majority of these prescriptions are fulfilled through the Prime Vendor contract, CMOP supplements its supply through Open Market (OM) purchases when necessary, through solicitations that get published to the System for Award Management (SAM) website, similar to how this RFI is being published.\n\nTo support these OM requirements, the Government has an ongoing need to identify pharmaceutical end items manufactured, processed, or produced by domestic small and large businesses. This RFI is issued solely for market research and procurement planning purposes and does not constitute a Request for Quote (RFQ) or Request for Proposal (RFP). This notice shall not be construed as a commitment by the Government to ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. This request does not constitute a solicitation for proposals or quotes or the authority to enter into negotiations to award a contract. No funds have been authorized, appropriated, or received for this effort. Related details can be found in section six (6) regarding the nature of this RFI.\n2. Purpose\nThe purpose of this RFI is to:\nIdentify domestic small and large business pharmaceutical manufacturers with efficient production capabilities related to FAR Part 12 Acquisition of Commercial Products and Commercials Services in combination with FAR Part 25 Foreign Acquisition procedures.\nGather information on manufacturers of pharmaceuticals and ancillary items related to CMOP s OM purchases.\nPromote early exchanges of information in accordance with Federal Acquisition Regulation (FAR) Overhaul Part 15.101, to improve mutual understanding of Government needs and industry capabilities.\nDeeper Insight into Small Business type considerations in manufacturing to include all socio-economic considerations with the highest interest in Service-Disabled Veteran Owned Small Businesses (SDVOSB) and Veteran Owned Small Business (VOSB) Manufacturers.\n3. Scope\nThe overall intent of the RFI is to provide outreach within the designated NAICS codes:\n325412 - Pharmaceutical Preparation Manufacturing\n325413 - In-Vitro Diagnostic Substance Manufacturing \nThe list presented below is not exhaustive of pharmaceutical and medical surgical items that may be required in Fiscal Year (FY) 26 and is subject to be updated periodically as our requirements change. \nCMOP is seeking information from both small and large domestic manufacturers capable of providing the following items to support CMOP s OM needs:\nStation item #\nPharmaceutical Description\nTreatment\n16822\nABALOPARATIDE 80MCG/O.04ML PEN 156ML\nUsed for those who suffer from high risk osteoporosis\n10834\nACAMPROSATE CA 333MG TAB\nUsed to help overcome alcoholism\n18491\nARMODAFINIL 250MGTAB\nUsed to treat excessive sleepiness (narcolepsy)\n12784\nARMODAFINIL 50MG TAB\nUsed to treat excessive sleepiness (narcolepsy)\n2955\nARTIFICIAL SALIVA ORAL SPRAY\nUsed to treat dry mouth or bad breath\n13125\nBREAST MILK, STORAGE BAGS, 100ct\nUsed to store breast milk\n15663\nBRIMONIDINE TARTRATE 0.025% OPH SOLN\nUsed to lower pressure inside the eye\n12679\nCALCIUM 500MG/VITAMIN D 500UNIT CHEW TAB\nUsed to treat low calcium and vitamin D levels\n13707\nCARBOXYMETHYLCELLULOSE NA 0.25% OPH SOLN 15ML\nUsed to treat dry eyes\nXV066\nCATH SET, INTERMIT 14FR H#96144\nUsed to drain the bladder\nXT265\nCATH,EXTERNAL EXTENDED WEAR MED H#9207\nUsed to drain the bladder\nC0820\nCLINDAMYCIN P04 1% TOP SWAB\nUsed to treat acne lesions\nC0482\nCLOMIPHENE CITRATE 50MG TAB\nUsed to induce ovulation (egg production)\nC0731\nCOAL TAR 2% SHAMPOO\nUsed to treat eczema, psoriasis, dermatitis, and other skin disorders\nC0609\nCOLESTIPOL HCL 1GM TAB\nUsed to lower high cholesterol levels in the blood\nD0025\nDESONIDE 0.05% CREAM,TOP\nUsed to relieve redness, itching and other discomfort caused by skin conditions\nD0938\nDORZOLAMIDE 22.3/TIMOLOL6.8MG/ML PF OPH\nused to treat increased pressure in the eye\nD0828\nDORZOLAMIDE 22.3_TIMOLOL6.8MG_ML OPH SOL\nUsed to treat increased pressure in the eye\nXH825\nDRESSING,DRAWTEX 4IN X 4IN\nTreatment in wound care\nD1217\nDROSPIRENONE 4MG TAB,28\nUsed to prevent ovulation and pregnancy\nD0922\nDULOXETINE HCL 20MG EC CAP\nUsed to treat depression and anxiety\nD0929\nDULOXETINE HCL 30MG EC CAP\nUsed to treat depression and anxiety\nD0924\nDULOXETINE HCL 60MG EC CAP\nUsed to treat depression and anxiety\nXJ196\nELECTRODE PAD EARCLIP AS#EEP\nUsed with an electrotherapy stimulator for the treat anxiety, depression, and insomnia\nE0811\nESOMEPRAZOLE 20MG (BASE) EC CAP\nUsed for the treatment of erosive esophagitis\nE0301\nEYELID CLEANSER,EYE SCRUB PAD\nUsed to maintain ocular surface health for patients with blepharitis, MGD, and demodex infections\nXK812\nFEMALE CONDOM,INTERNAL\nUsed to help prevent pregnancy and reduce the risk of sexually transmitted diseases\nF0355\nFENOFIBRATE 145MG TAB\nUsed to reduce elevated low-density lipoprotein cholesterol\nF0354\nFENOFIBRATE 48MG TAB\nUsed to reduce elevated low-density lipoprotein cholesterol\nF0423\nFESOTERODINE FUMARATE 4MG SA TAB\nUsed for the treatment of overactive bladder\nF0135\nFOSINOPRIL NA 40MG TAB 90CT\nUsed for the treatment of hypertension\nG0257\nGALANTAMINE HYDROBROMIDE 8MG SA CAP\nTreatment of mild to moderate dementia of the Alzheimer's\nG0194\nGLIPIZIDE 2.5MG SA TAB\nUsed to improve glycemic control in adults with diabetes\nH0066\nHYDROCORTISONE ACETATE 25MG RTL SUPP\nUsed to treat hemorrhoids\nI0004\nIBUPROFEN 400MG TAB\nUsed to treat pain, fever, and inflammation\nI0005\nIBUPROFEN 600MG TAB\nUsed to treat pain, fever, and inflammation\nI0006\nIBUPROFEN 800MG TAB\nUsed to treat pain, fever, and inflammation\nJ0040\nJASMIEL TAB,28\nUsed to prevent pregnancy\nL0329\nLANSOPRAZOLE 15MG SA DISINTEGRATING TAB\nTreatment of ulcers\nL0330\nLANSOPRAZOLE 30MG SA DISINTEGRATING TAB\nTreatment of ulcers\nXZ156\nLEG BAG COMBINATION PK H#9349 LATEX FREE\nUsed to collect urine through a catheter drain tube\nL0780\nLEVODOPA 42MG INHL CAP\nUsed in the treatment of Parkinson disease as a dopamine replacement\n\nLEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB\nused to treat different types of bacterial infections.\nM1295\nMETFORMIN (EQV-FORTAMET) 1000MG SA TAB\nManagement of type 2 diabetes\nM0103\nMINOCYCLINE HCL 50MG CAP\nUsed to treat infections cased by bacteria\nN0567\nNEBIVOLOL 5MG TAB\nUsed to treat high blood pressure\nXZ173\nONE TOUCH ULTRA (GLUCOSE) TEST STRIPS 50CT & 100CT\nUsed to test blood glucose levels in managing type 1 & 2 diabetes\nXH026\nPAD,NURSING DISPOSABLE\nUsed on breast feeding mothers to absorb any milk that may leak between feedings\nP0535\nPIOGLITAZONE HCL 15MG TAB\nManagement of type 2 diabetes\nP0536\nPIOGLITAZONE HCL 30MG TAB\nManagement of type 2 diabetes\nP0537\nPIOGLITAZONE HCL 45MG TAB\nManagement of type 2 diabetes\nP0110\nPREDNISONE 1MG TAB 1000CT\nCorticosteriod used on the immune system to help relieve swelling, redness, itching, and allergic reactions\nP0156\nPROPRANOLOL HCL 60MG SA CAP - 33030\nused to treat high blood pressure\nP0175\nPYRIDOSTIGMINE BROMIDE 60MG TAB\nUsed to treat myasthenia gravis muscle weakness\nR0233\nRESOURCE BENEPROTEIN PWDR,227GM\nused to supply protein needed to help maintain muscle. For patients that can t eat food.\nXJ330\nSET,INFUSION AUTOSOFT XC TANDEM #1001680\nUsed to manage diabetes by delivering insulin from a pump to the body\nXJ441\nSET,INFUSION AUTOSOFT XC TANDEM #1001729\nUsed to manage diabetes by delivering insulin from a pump to the body\nS0578\nSEVELAMER CARBONATE 800MG TAB\nFor the control of serum phosphorus in adults with chronic kidney disease on dialysis\nS0167\nSODIUM CHLORIDE 2% OPH SOLN\nUsed to reduce surface corneal swelling of the eye\nS0174\nSUMATRIPTAN 6MG_0.5ML INJ SYRINGE 0.5ML\nUsed for treatment of migraines\nU0004\nUREA 40% CREAM\nUsed to treat dry/rough skin conditions and some nail problems\nZ0005\nZINC OXIDE 20% OINT (60GM & 464GM)\nUsed to treat or prevet skin irritation\nZ0067\nZOLPIDEM TARTRATE 12.5MG SA TAB\nUsed to treat insomnia\n4. Submission Guidelines\nIf your company manufactures pharmaceuticals that are not listed above and are produced domestically in accordance with (IAW) FAR Part 25.001(c), please provide the following information:\nCompany Information:\nName, physical address, and point of contact\nPhysical address of domestic manufacturing facility\nSocioeconomic status (e.g., SDVOSB, VOSB, 8(a), etc.) to include both large and small business types\nBusiness size and SAM UEI Number\n\nProduct Information:\nList of domestically manufactured pharmaceuticals\nFDA-approved NDC numbers\nTreatment usage of each pharmaceutical\nAuthorized distributors\nAverage cost for common prescription quantities\nOperational Capability:\nManufacturing facility production capacity (volume)\nFrequency of stockouts in the past 12 months\nTypical replenishment timelines\nCommercial entities where the items have been sold to for ultimate large volume dispensing.\nContracting Information:\nGSA/FSS/NAC contract numbers (if applicable)\nSuggested alternative NAICS or PSC codes, if more appropriate\nCompliance:\nAny manufacturer responding to this announcement must be able to show their capability to comply with:\nAbility to meet federal, state, and local regulations\nCapacity to support all seven CMOP sites if needed\nInterested manufacturers are reminded that in accordance with FAR 4.12, prospective contractors shall complete electronic annual representations and certifications in conjunction with FAR 4.11 required registration in the System for Award Management (SAM) database prior to award of a contract. \n5. Response Instructions:\nIf you believe you are capable of meeting the requirement, please provide a complete capability statement and response by March 15, 2026, at 4:30 pm CT to:\nMichael McAlhaney \nEmail: michael.mcalhaney@va.gov\nTresanna Tacia\nEmail: tresanna.tacia@va.gov\n\nSubject Line of Email: Must start with the 1) RFI Number 36C77026Q0061 followed by the 2) generic pharmaceutical name. The proprietary name should only be used when there are no FDA approved generic options. \n\nUse the Excel Spreadsheet inputs as identified as Manufacturer Inputs_Excel as part of a complete submission.\n6. Important Notice\nPLEASE NOTE: This RFI is issued solely for information and planning purposes only and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. Respondents are solely responsible for all expenses associated with responding to this RFI. The Government does not intend to award a contract on the basis of the RFI or otherwise pay for the information requested. Responses will be treated as information only and not as a proposal.\n\n"} Solicitation Number: 36C77026Q0061 Type: Sources Sought Base Type: Sources Sought NAICS: 325412 Classification Code: 6505 Response Deadline: 2026-03-16T09:00:00-05:00 Office Address: LEAVENWORTH, KS POC: McAlhaney, Michael W., Michael.McAlhaney@va.gov, (913) 684-1976 {"description":"36C77026Q0061\nRequest for Information (RFI): \nDomestic Pharmaceutical Manufacturing 36C77026Q0061\n1. Overview\nThe Department of Veterans Affairs (VA), Consolidated Mail Outpatient Pharmacy (CMOP) operates seven sites across the United States, supporting the daily mailout of approximately 450,000 prescriptions to Veterans. While the majority of these prescriptions are fulfilled through the Prime Vendor contract, CMOP supplements its supply through Open Market (OM) purchases when necessary, through solicitations that get published to the System for Award Management (SAM) website, similar to how this RFI is being published.\n\nTo support these OM requirements, the Government has an ongoing need to identify pharmaceutical end items manufactured, processed, or produced by domestic small and large businesses. This RFI is issued solely for market research and procurement planning purposes and does not constitute a Request for Quote (RFQ) or Request for Proposal (RFP). This notice shall not be construed as a commitment by the Government to ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. This request does not constitute a solicitation for proposals or quotes or the authority to enter into negotiations to award a contract. No funds have been authorized, appropriated, or received for this effort. Related details can be found in section six (6) regarding the nature of this RFI.\n2. Purpose\nThe purpose of this RFI is to:\nIdentify domestic small and large business pharmaceutical manufacturers with efficient production capabilities related to FAR Part 12 Acquisition of Commercial Products and Commercials Services in combination with FAR Part 25 Foreign Acquisition procedures.\nGather information on manufacturers of pharmaceuticals and ancillary items related to CMOP s OM purchases.\nPromote early exchanges of information in accordance with Federal Acquisition Regulation (FAR) Overhaul Part 15.101, to improve mutual understanding of Government needs and industry capabilities.\nDeeper Insight into Small Business type considerations in manufacturing to include all socio-economic considerations with the highest interest in Service-Disabled Veteran Owned Small Businesses (SDVOSB) and Veteran Owned Small Business (VOSB) Manufacturers.\n3. Scope\nThe overall intent of the RFI is to provide outreach within the designated NAICS codes:\n325412 - Pharmaceutical Preparation Manufacturing\n325413 - In-Vitro Diagnostic Substance Manufacturing \nThe list presented below is not exhaustive of pharmaceutical and medical surgical items that may be required in Fiscal Year (FY) 26 and is subject to be updated periodically as our requirements change. \nCMOP is seeking information from both small and large domestic manufacturers capable of providing the following items to support CMOP s OM needs:\nStation item #\nPharmaceutical Description\nTreatment\n16822\nABALOPARATIDE 80MCG/O.04ML PEN 156ML\nUsed for those who suffer from high risk osteoporosis\n10834\nACAMPROSATE CA 333MG TAB\nUsed to help overcome alcoholism\n18491\nARMODAFINIL 250MGTAB\nUsed to treat excessive sleepiness (narcolepsy)\n12784\nARMODAFINIL 50MG TAB\nUsed to treat excessive sleepiness (narcolepsy)\n2955\nARTIFICIAL SALIVA ORAL SPRAY\nUsed to treat dry mouth or bad breath\n13125\nBREAST MILK, STORAGE BAGS, 100ct\nUsed to store breast milk\n15663\nBRIMONIDINE TARTRATE 0.025% OPH SOLN\nUsed to lower pressure inside the eye\n12679\nCALCIUM 500MG/VITAMIN D 500UNIT CHEW TAB\nUsed to treat low calcium and vitamin D levels\n13707\nCARBOXYMETHYLCELLULOSE NA 0.25% OPH SOLN 15ML\nUsed to treat dry eyes\nXV066\nCATH SET, INTERMIT 14FR H#96144\nUsed to drain the bladder\nXT265\nCATH,EXTERNAL EXTENDED WEAR MED H#9207\nUsed to drain the bladder\nC0820\nCLINDAMYCIN P04 1% TOP SWAB\nUsed to treat acne lesions\nC0482\nCLOMIPHENE CITRATE 50MG TAB\nUsed to induce ovulation (egg production)\nC0731\nCOAL TAR 2% SHAMPOO\nUsed to treat eczema, psoriasis, dermatitis, and other skin disorders\nC0609\nCOLESTIPOL HCL 1GM TAB\nUsed to lower high cholesterol levels in the blood\nD0025\nDESONIDE 0.05% CREAM,TOP\nUsed to relieve redness, itching and other discomfort caused by skin conditions\nD0938\nDORZOLAMIDE 22.3/TIMOLOL6.8MG/ML PF OPH\nused to treat increased pressure in the eye\nD0828\nDORZOLAMIDE 22.3_TIMOLOL6.8MG_ML OPH SOL\nUsed to treat increased pressure in the eye\nXH825\nDRESSING,DRAWTEX 4IN X 4IN\nTreatment in wound care\nD1217\nDROSPIRENONE 4MG TAB,28\nUsed to prevent ovulation and pregnancy\nD0922\nDULOXETINE HCL 20MG EC CAP\nUsed to treat depression and anxiety\nD0929\nDULOXETINE HCL 30MG EC CAP\nUsed to treat depression and anxiety\nD0924\nDULOXETINE HCL 60MG EC CAP\nUsed to treat depression and anxiety\nXJ196\nELECTRODE PAD EARCLIP AS#EEP\nUsed with an electrotherapy stimulator for the treat anxiety, depression, and insomnia\nE0811\nESOMEPRAZOLE 20MG (BASE) EC CAP\nUsed for the treatment of erosive esophagitis\nE0301\nEYELID CLEANSER,EYE SCRUB PAD\nUsed to maintain ocular surface health for patients with blepharitis, MGD, and demodex infections\nXK812\nFEMALE CONDOM,INTERNAL\nUsed to help prevent pregnancy and reduce the risk of sexually transmitted diseases\nF0355\nFENOFIBRATE 145MG TAB\nUsed to reduce elevated low-density lipoprotein cholesterol\nF0354\nFENOFIBRATE 48MG TAB\nUsed to reduce elevated low-density lipoprotein cholesterol\nF0423\nFESOTERODINE FUMARATE 4MG SA TAB\nUsed for the treatment of overactive bladder\nF0135\nFOSINOPRIL NA 40MG TAB 90CT\nUsed for the treatment of hypertension\nG0257\nGALANTAMINE HYDROBROMIDE 8MG SA CAP\nTreatment of mild to moderate dementia of the Alzheimer's\nG0194\nGLIPIZIDE 2.5MG SA TAB\nUsed to improve glycemic control in adults with diabetes\nH0066\nHYDROCORTISONE ACETATE 25MG RTL SUPP\nUsed to treat hemorrhoids\nI0004\nIBUPROFEN 400MG TAB\nUsed to treat pain, fever, and inflammation\nI0005\nIBUPROFEN 600MG TAB\nUsed to treat pain, fever, and inflammation\nI0006\nIBUPROFEN 800MG TAB\nUsed to treat pain, fever, and inflammation\nJ0040\nJASMIEL TAB,28\nUsed to prevent pregnancy\nL0329\nLANSOPRAZOLE 15MG SA DISINTEGRATING TAB\nTreatment of ulcers\nL0330\nLANSOPRAZOLE 30MG SA DISINTEGRATING TAB\nTreatment of ulcers\nXZ156\nLEG BAG COMBINATION PK H#9349 LATEX FREE\nUsed to collect urine through a catheter drain tube\nL0780\nLEVODOPA 42MG INHL CAP\nUsed in the treatment of Parkinson disease as a dopamine replacement\n\nLEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB\nused to treat different types of bacterial infections.\nM1295\nMETFORMIN (EQV-FORTAMET) 1000MG SA TAB\nManagement of type 2 diabetes\nM0103\nMINOCYCLINE HCL 50MG CAP\nUsed to treat infections cased by bacteria\nN0567\nNEBIVOLOL 5MG TAB\nUsed to treat high blood pressure\nXZ173\nONE TOUCH ULTRA (GLUCOSE) TEST STRIPS 50CT & 100CT\nUsed to test blood glucose levels in managing type 1 & 2 diabetes\nXH026\nPAD,NURSING DISPOSABLE\nUsed on breast feeding mothers to absorb any milk that may leak between feedings\nP0535\nPIOGLITAZONE HCL 15MG TAB\nManagement of type 2 diabetes\nP0536\nPIOGLITAZONE HCL 30MG TAB\nManagement of type 2 diabetes\nP0537\nPIOGLITAZONE HCL 45MG TAB\nManagement of type 2 diabetes\nP0110\nPREDNISONE 1MG TAB 1000CT\nCorticosteriod used on the immune system to help relieve swelling, redness, itching, and allergic reactions\nP0156\nPROPRANOLOL HCL 60MG SA CAP - 33030\nused to treat high blood pressure\nP0175\nPYRIDOSTIGMINE BROMIDE 60MG TAB\nUsed to treat myasthenia gravis muscle weakness\nR0233\nRESOURCE BENEPROTEIN PWDR,227GM\nused to supply protein needed to help maintain muscle. For patients that can t eat food.\nXJ330\nSET,INFUSION AUTOSOFT XC TANDEM #1001680\nUsed to manage diabetes by delivering insulin from a pump to the body\nXJ441\nSET,INFUSION AUTOSOFT XC TANDEM #1001729\nUsed to manage diabetes by delivering insulin from a pump to the body\nS0578\nSEVELAMER CARBONATE 800MG TAB\nFor the control of serum phosphorus in adults with chronic kidney disease on dialysis\nS0167\nSODIUM CHLORIDE 2% OPH SOLN\nUsed to reduce surface corneal swelling of the eye\nS0174\nSUMATRIPTAN 6MG_0.5ML INJ SYRINGE 0.5ML\nUsed for treatment of migraines\nU0004\nUREA 40% CREAM\nUsed to treat dry/rough skin conditions and some nail problems\nZ0005\nZINC OXIDE 20% OINT (60GM & 464GM)\nUsed to treat or prevet skin irritation\nZ0067\nZOLPIDEM TARTRATE 12.5MG SA TAB\nUsed to treat insomnia\n4. Submission Guidelines\nIf your company manufactures pharmaceuticals that are not listed above and are produced domestically in accordance with (IAW) FAR Part 25.001(c), please provide the following information:\nCompany Information:\nName, physical address, and point of contact\nPhysical address of domestic manufacturing facility\nSocioeconomic status (e.g., SDVOSB, VOSB, 8(a), etc.) to include both large and small business types\nBusiness size and SAM UEI Number\n\nProduct Information:\nList of domestically manufactured pharmaceuticals\nFDA-approved NDC numbers\nTreatment usage of each pharmaceutical\nAuthorized distributors\nAverage cost for common prescription quantities\nOperational Capability:\nManufacturing facility production capacity (volume)\nFrequency of stockouts in the past 12 months\nTypical replenishment timelines\nCommercial entities where the items have been sold to for ultimate large volume dispensing.\nContracting Information:\nGSA/FSS/NAC contract numbers (if applicable)\nSuggested alternative NAICS or PSC codes, if more appropriate\nCompliance:\nAny manufacturer responding to this announcement must be able to show their capability to comply with:\nAbility to meet federal, state, and local regulations\nCapacity to support all seven CMOP sites if needed\nInterested manufacturers are reminded that in accordance with FAR 4.12, prospective contractors shall complete electronic annual representations and certifications in conjunction with FAR 4.11 required registration in the System for Award Management (SAM) database prior to award of a contract. \n5. Response Instructions:\nIf you believe you are capable of meeting the requirement, please provide a complete capability statement and response by March 15, 2026, at 4:30 pm CT to:\nMichael McAlhaney \nEmail: michael.mcalhaney@va.gov\nTresanna Tacia\nEmail: tresanna.tacia@va.gov\n\nSubject Line of Email: Must start with the 1) RFI Number 36C77026Q0061 followed by the 2) generic pharmaceutical name. The proprietary name should only be used when there are no FDA approved generic options. \n\nUse the Excel Spreadsheet inputs as identified as Manufacturer Inputs_Excel as part of a complete submission.\n6. Important Notice\nPLEASE NOTE: This RFI is issued solely for information and planning purposes only and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. Respondents are solely responsible for all expenses associated with responding to this RFI. The Government does not intend to award a contract on the basis of the RFI or otherwise pay for the information requested. Responses will be treated as information only and not as a proposal.\n\n"}